pharmaphorum September 6, 2024
In its second R&D alliance this week, Eli Lilly has formed a partnership with Genetic Leap, a startup that focuses on applying artificial intelligence to the discovery of RNA-targeted therapies.
Under the terms of the deal, privately-held Genetic Leap is in line for upfront and milestone payments of up to $409 million, as well as tiered royalties. It builds on a pilot between the two companies and will focus on the discovery of oligonucleotide drugs against targets selected by Lilly in “high-priority therapeutic areas.”
The agreement ties in with Lilly’s strategy of making genetic medicines targeting DNA and RNA a key pillar of its R&D, accounting for more than 25% of its therapeutic pipeline and focusing on common conditions like...
Today's Sponsors
Today's Sponsor